90 related articles for article (PubMed ID: 24403504)
21. Treatment of ALK-positive non-small cell lung cancer.
Bang YJ
Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
23. The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer.
Galetta D; Rossi A; Pisconti S; Colucci G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S45-54. PubMed ID: 22443113
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
Mendoza L
Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapy for lung cancer: present and future.
Aggarwal C
Ann Palliat Med; 2014 Jul; 3(3):229-35. PubMed ID: 25841697
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
Marchetti C; Palaia I; De Felice F; Musella A; Donfracesco C; Vertechy L; Romito A; Piacenti I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Cancer Treat Rev; 2016 Jan; 42():41-6. PubMed ID: 26559739
[TBL] [Abstract][Full Text] [Related]
27. Progress in the Management of Advanced Thoracic Malignancies in 2017.
Ferrara R; Mezquita L; Besse B
J Thorac Oncol; 2018 Mar; 13(3):301-322. PubMed ID: 29331646
[TBL] [Abstract][Full Text] [Related]
28. Emerging new anticancer biological therapies in 2013 (haematological malignancies).
Plawny L; Ries F
Curr Opin Oncol; 2014 May; 26(3):363-70. PubMed ID: 24663027
[TBL] [Abstract][Full Text] [Related]
29. Advances in kinase targeting: current clinical use and clinical trials.
Rask-Andersen M; Zhang J; Fabbro D; Schiöth HB
Trends Pharmacol Sci; 2014 Nov; 35(11):604-20. PubMed ID: 25312588
[TBL] [Abstract][Full Text] [Related]
30. DNA synthesis inhibitors for the treatment of gastrointestinal cancer.
Yasui H; Tsurita G; Imai K
Expert Opin Pharmacother; 2014 Nov; 15(16):2361-72. PubMed ID: 25256052
[TBL] [Abstract][Full Text] [Related]
31. Protein Kinase Targets in Breast Cancer.
García-Aranda M; Redondo M
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186886
[TBL] [Abstract][Full Text] [Related]
32. Thymic malignancies: Moving forward with new systemic treatments.
Remon J; Lindsay CR; Bluthgen MV; Besse B
Cancer Treat Rev; 2016 May; 46():27-34. PubMed ID: 27057658
[TBL] [Abstract][Full Text] [Related]
33. [Management of the cardiovascular complications of treatment in thoracic oncology].
Ederhy S; Hollebecque A; Haddour N; Massard C; Fleury G; Ferte C; Adavane S; Besse B; Boccara F; Soria JC; Cohen A
Rev Mal Respir; 2014 Feb; 31(2):173-80. PubMed ID: 24602684
[TBL] [Abstract][Full Text] [Related]
34. Thymic malignancies: emerging systemic therapies.
Girard N
Curr Opin Oncol; 2019 Sep; 31(5):454-460. PubMed ID: 31394557
[TBL] [Abstract][Full Text] [Related]
35. [Mechanisms of resistance to molecular targeted drugs].
Fujita N
Nihon Rinsho; 2014 Jun; 72(6):1151-6. PubMed ID: 25016819
[TBL] [Abstract][Full Text] [Related]
36. Scientific Advances in Thoracic Oncology 2016.
Soo RA; Stone ECA; Cummings KM; Jett JR; Field JK; Groen HJM; Mulshine JL; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck FC; Lim E; Asamura H; Donington J; Wakelee HA; Wu YL; Higgins K; Senan S; Solomon B; Kim DW; Johnson M; Yang JCH; Sequist LV; Shaw AT; Ahn MJ; Costa DB; Patel JD; Horn L; Gettinger S; Peters S; Wynes MW; Faivre-Finn C; Rudin CM; Tsao A; Baas P; Kelly RJ; Leighl NB; Scagliotti GV; Gandara DR; Hirsch FR; Spigel DR
J Thorac Oncol; 2017 Aug; 12(8):1183-1209. PubMed ID: 28579481
[TBL] [Abstract][Full Text] [Related]
37. Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform.
Morfouace M; Novello S; Stevovic A; Dooms C; Janžič U; Berghmans T; Dziadziuszko R; Gorlia T; Felip E; Paz-Ares L; Mazieres J; O'Brien M; Bironzo P; Vansteenkiste J; Lacroix L; Dingemans AC; Golfinopoulos V; Besse B
Sci Rep; 2022 May; 12(1):8342. PubMed ID: 35585228
[TBL] [Abstract][Full Text] [Related]
38. Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways.
Mountzios G; Banna GL; Rolfo C
Front Oncol; 2022; 12():997404. PubMed ID: 36185302
[No Abstract] [Full Text] [Related]
39. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
Janku F; Angenendt P; Tsimberidou AM; Fu S; Naing A; Falchook GS; Hong DS; Holley VR; Cabrilo G; Wheler JJ; Piha-Paul SA; Zinner RG; Bedikian AY; Overman MJ; Kee BK; Kim KB; Kopetz ES; Luthra R; Diehl F; Meric-Bernstam F; Kurzrock R
Oncotarget; 2015 Sep; 6(27):24581. PubMed ID: 26405159
[TBL] [Abstract][Full Text] [Related]
40. Editorial: Mechanisms of drug resistance to targeted therapy in malignancies.
Hamaji M
Front Oncol; 2024; 14():1363808. PubMed ID: 38313799
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
